Toward the discovery of dual HCMV–VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides
Links to Files
Author/Creator ORCID
Date
Type of Work
Department
Program
Citation of Original Publication
Babkov, Denis A., Anastasia L. Khandazhinskaya, Alexander O. Chizhov, Graciela Andrei, Robert Snoeck, Katherine L. Seley-Radtke, and Mikhail S. Novikov. “Toward the Discovery of Dual HCMV–VZV Inhibitors: Synthesis, Structure Activity Relationship Analysis, and Cytotoxicity Studies of Long Chained 2-Uracil-3-Yl-N-(4-Phenoxyphenyl)Acetamides.” Bioorganic & Medicinal Chemistry 23, no. 21 (November 1, 2015): 7035–44. https://doi.org/10.1016/j.bmc.2015.09.033.
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Abstract
The need for novel therapeutic options to fight herpesvirus infections still persists. Herein we report the design, synthesis and antiviral evaluation of a new family of non-nucleoside antivirals, derived from 1-[ω-(4-bromophenoxy)alkyl]uracil derivatives – previously reported inhibitors of human cytomegalovirus (HCMV). Introduction of the N-(4-phenoxyphenyl)acetamide side chain at N3 increased their potency and widened activity spectrum. The most active compounds in the series exhibit submicromolar activity against different viral strains of HCMV and varicella zoster virus (VZV) replication in HEL cell cultures. Inactivity against other DNA and RNA viruses, including herpes simplex virus 1/2, points to a novel mechanism of antiviral action.